Affy Stock Slides 13 Percent on Weak Q2 as Banks Downgrade Shares and Temper Outlook | GenomeWeb
NEW YORK (GenomeWeb News) – Shares in Affymetrix were down approximately 13 percent, or $2.72, at $18.85 in mid-afternoon trading today after the company yesterday posted a $10.1 million net loss and a 4.7-percent decline in revenue for the second quarter.
 
The stock is currently trading at levels not seen since 2003.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: genetic analysis of pollutant-tolerant fish, and more.

Researchers have found a rare carbapenem resistance gene on a US pig farm, NBC News reports.

New York officials are considering the use of a familial DNA search to get a lead on a suspect in the strangulation death of a runner.

NIH Director Francis Collins has selected a retired Army major general and cardiologist for the CEO spot at the agency's embattled Clinical Center.